Tech Company Financing Transactions
Sirnaomics Funding Round
Sirnaomics closed a $105 million Series E funding round on 7/5/2021. Investors included Rotating Boulder Capital and private investors.
Transaction Overview
Company Name
Announced On
7/5/2021
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series E
Investors
Rotating Boulder Capital (Lead Investor)
Proceeds Purpose
Proceeds from the financing will be used to fund the continued development of Sirnaomics' novel RNAi therapeutics for treating diverse human disorders, which include cancers, viral infections, fibrosis, and metabolic diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
401 Professional Dr. 280
Gaithersburg, MD 20879
USA
Gaithersburg, MD 20879
USA
Phone
Website
Email Address
Overview
Sirnaomics, Inc. is a biopharmaceutical company discovering and developing novel targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patrick Lu
Chief Medical Officer
Michael Molyneaux
Chief Operating Officer
George Ji
Chief Scientific Officer
David Evans
Chief Technical Officer
Dmitry Samarsky
VP - Finance
Nigel Yip
VP - Human Resources
John Buergenthal
Browse more venture capital transactions:
Prev: 7/5/2021: Karat Financial venture capital transaction
Next: 7/5/2021: Physna venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs